Alemtuzumab for multiple sclerosis: who and when to treat?

Lancet. 2012 Nov 24;380(9856):1795-7. doi: 10.1016/S0140-6736(12)61859-5. Epub 2012 Nov 2.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Interferon beta-1a
  • Interferon-beta / administration & dosage*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Peptides / administration & dosage*

Substances

  • Adjuvants, Immunologic
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Peptides
  • Alemtuzumab
  • Glatiramer Acetate
  • Interferon-beta
  • Interferon beta-1a